



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

GSHISHIMA@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598


March 1, 2005

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

March 1, 2005

Date



Gina N. Shishima

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/791,692 entitled "METHODS AND COMPOSITIONS INVOLVING MDA-7" – by Sunil Chada, et al.*
Our reference: INGN:105US
U.T. Ref. MDA03-090

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and reference B9 and C134-136.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INGN:105US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104

GNS/kvp
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Sunil Chada, et al.

Serial No.: 10/791,692

Filed: March 2, 2004

For: METHODS AND COMPOSITIONS
INVOLVING MDA-7

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: INGN:105US

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

March 1, 2005

Date

Gina N. Shishima

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of cited U.S. patents, U. S. patent application publications and co-pending U.S. patent applications have not been enclosed subject to the waiver regarding the requirement under 37 C.F.R. §1.98(a)(2)(i) stated in the Official Gazette Notice dated August 5, 2003 regarding patent applications filed on or after June 30, 2003.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INGN:105US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 1, 2005

Form PTO-1449 (modified)

MAR 03 2005

Atty. Docket No.
INGN:105USSerial No.
10/791,692

List of Patents and Publications for Applicant

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
March 2, 2004Group:
1645

U.S. Patent Documents
See Page 1

Foreign Patent Documents
See Page 1

Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A39	6,207,648	3/27/01	Waxman <i>et al.</i>	514	44	7/17/97
	A40	6,855,686	2/15/05	Fisher	514	2	11/21/01

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B9	WO 95/28948	11/02/95	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C134	Davis, "The many faces of epidermal growth factor repeats," <i>The New Biologist</i> , 2(5):410-419, 1990.
	C135	Dillman, "Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer," <i>Cancer Biotherapy & Radiopharmaceuticals</i> , 14(1):5-10, 1999.
	C136	Nishisaka <i>et al.</i> , "Immunotherapy and gene therapy for renal cell carcinoma," <i>Urol Oncol</i> , 3:148-153, 1997.

25506865.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.